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Pain is perceived and then it is operated on in the cerebral cortex by several processes such as transduction, transmission,
modulation and perception. We have to know the exact mechanism of pain. The purpose of this review is to explain the
mechanisms of pain and to discuss the definitions of the terms related to pain. We also review the mechanisms of the anal-
gesic effect of the pharmaceuticals we use to control pain. 
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Introduction
The International Association for the Study of Pain
defines pain as an unpleasant sensory and emotional experi-
ence associated with actual or potential tissue damage, or
describes it in terms of such damage. This groups commit-
tee on taxonomy goes on to state,  ‘If a patient regards their
experience as pain and if they report it in the same way as
pain caused by tissue damage, it should be accepted as
pain’. Therefore, not all pain is the result of a nociceptive
stimulus received and transmitted by a sensory receptor of a
peripheral nerve [1,2]. 
The general approach to patients complaining of pain is
that it is real. Pain has both physical and psychological
components that may predominate and alter the personality
of the individual. This change in personality usually returns
to the pre-pain state when the physical cause of the discom-
fort has been addressed. In addition, pain always has a sub-
jective component that is perceived by patients in relation to
previous experiences with pain, usually from their early
years. 
This review examines the mechanisms of the pain, dis-
cusses the definitions of the terms related to pain, and eval-
uates the mechanisms of the analgesic effect of pain med-
ications. 
The Mechanism of Pain 
Pain is perceived and operated by the cerebral cortex
through several processes; transduction, transmission, mod-
ulation and perception. The afferent fibers that convey noci-
ception are the group A-delta and C fibers (Fig. 1). The pri-
mary afferent fibers from the peripheral nociceptors
synapse with secondary order neurons at the dorsal horn in
the spinal cord, conveying the pain sense [3]. Thin A-delta
and C fibers synapse at laminas I and II, whereas thick A
fibers synapse at lamina IV. The fibers then conduct the
impulse to the brain (Fig. 2). A-beta fibers are related to
chronic pain, particularly neuropathic pain. 
1. Acute pain 
Peripheral nociceptive stimuli eventually releases gluta-
mate, which combines with the alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic-acid (AMPA)  receptor and
triggers the signal to the central nervous system. There are 4
pain inhibition mechanisms that may counteract this stimu-
lus: the descending inhibitory pathway, hypophysis-pitu-
itary-adrenal axis activity, glucocorticoid mediated pain
inhibition by a cytokine block, and the analgesic function of
the limbic system between S1. In acute pain, all 4 pain inhi-
bition processes are working normally [4]. 
2. Chronic pain
Chronic pain is mediated primarily by the N-methyl-D-
aspartate (NMDA) receptor. Glutamate release stimulated
by the acute pain signal cannot activate the NMDA receptor
due to a magnesium ion block. Repetitive, continuous pain
signals and excessive glutamate release might activate the
NMDA receptor. The cascade of the intracellular calcium
ion influx, protein kinase C activation, nitric oxide produc-
tion and substance P release eventually occurs. The sub-
stance P released induces the expression of the c-fos gene,
which promotes neural remodeling and central hypersensiti-
zation. This mechanism is responsible for converting a
painful experience into a disease. In the case of chronic
pain, the 4 pain inhibition mechanisms are non-functional. 
Terms Related to Pain 
1. Nociceptor 
A nociceptor is defined as follows: “A receptor preferen-
tially sensitive to a noxious stimulus or to a stimulus which
would become noxious if prolonged.” All nociceptors are
specialized primary sensory neurons, whose cell bodies are
located in the dorsal root or trigeminal ganglia. The primary
sensory endings are normally in the periphery, and they
transmit their information into the central nervous system
(CNS) via central processes, such as the dorsal root ganglia
or trigeminal ganglia. Nociceptors convert the mechanical,
thermal, and chemical signals into action potentials that
synapse in the dorsal horn (or spinal nucleus of the trigemi-
nal nerve) onto second-order pain pathway neurons. The
pain pathways eventually reach the cortex and are interpret-
ed by the CNS as pain. In addition, the viscera and many
other tissues including the spinal tissues contain  “silent
nociceptors”that are not normally activated by noxious
stimuli. These receptors can be altered dramatically by
inflammation or chemical insults, resulting in a concomitant
increase in their firing rate. Therefore, these  “silent noci-
ceptors”can contribute to the development of secondary
hyperalgesia or central sensitization. 
2. Allodynia 
Allodynia is defined as “Pain due to a stimulus which
does not normally provoke pain.” This term is used to
describe conditions, in which a stimulus that is normally not
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Fig. 2. Projection neuron of the dorsal horn.
Fig. 1. Physiology of pain perception. DRG: Dorsal root gan-
glion.
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C fiberspainful is now considered painful because of some alter-
ation in the CNS. Most nociceptive afferent fibers entering
the dorsal horn undergo a high degree of divergence before
synapsing on their second-order pathways. The majority of
these synapse into interneurons that influence the overall
neural tone of the spinal cord associated with the spinal
reflexes, postural control, and the overall responsiveness of
the system. In general, the responsiveness of these interneu-
rons are normally suppressed by the descending supraspinal
pathways. After an injury, the increased afferent activity
associated with the nociceptive input may increase the over-
all output of the interneurons dramatically. Because of the
large number of interneurons present in the dorsal horn and
their subsequent activation by the increased nociceptive
input, the afferents of the nonnociceptive fibers may subse-
quently activate the nociceptive interneurons, thus trigger-
ing a painful response to a normally non-painful stimulus. 
3. Analgesia 
Analgesia is defined as an “Absence of pain in response
to stimulation which would normally be painful.” Because
pain is a perception controlled by the cerebral cortex, it can
be modulated in many ways to alter the incoming nocicep-
tive input and prevent the perception of a noxious stimulus.
Every synapse of the nociceptive input is a potential site for
modulation, and the CNS has a remarkable set of local
(spinal cord) interneurons and descending modulatory path-
ways designed exclusively to interrupt the conveyance of
nociceptive input. The perception of pain will be reduced or
eliminated if the nociceptive signal can be attenuated or
inhibited before reaching the cortex. In addition, exogenous
agents, such as aspirin or acetaminophen, can alter the bio-
chemical pathways responsible for the production of
inflammatory agents, thereby reducing their effect on the
nociceptors and thus their input into the CNS. Other agents,
such as morphine, can mimic the effects of the inhibitory
neurotransmitters and reduce the nociceptive input into the
CNS dramatically. 
4. Central pain 
Central pain is defined as  “Pain initiated or caused by a
primary lesion or dysfunction in the central nervous syst-
em.”Any disease process, trauma or space-occupying
lesion affecting the CNS can alter the normal functions of
the tracts, nuclei, and cell bodies of the nervous system,
including the somatosensory system. CNS has no sensory
afferents of its own, including nociceptors. Therefore, it
cannot normally detect the presence of these abnormalities.
However, changes in the normal functions indicate the pres-
ence of these pathologies. Both positive and negative signs
can exist after the lesions or dysfunctions occur within the
CNS. Positive signs (paresthesias) are sensations that nor-
mally are not present, but can be experienced after a lesion,
and include pain, dysesthesia or tingling sensations. Nega-
tive signs are those that normally are present but are no
longer perceptible, such as loss of position sense, touch or
pain. 
5. Hyperalgesia or sensitization 
Hyperalgesia or sensitization is defined as “An increased
response to a stimulus which is normally painful.” Hyperal-
gesia differs from allodynia in that hyperalgesia is an
increase in the sensitivity to pain due to a decrease in the
nociceptor’ s threshold for pain by either peripheral or cen-
tral mechanisms, whereas allodynia is a perception of pain
from a non-painful stimulus. Hyperalgesia can be classified
as either primary (peripheral) or secondary (central).
Primary hyperalgesia
This occurs at the site of an injury when the nociceptive
fiber is sensitized or stimulated directly by chemical agents
released by the damaged tissue and nearby cells or the neu-
ron itself. Substances, such as bradykinin, histamine,
prostaglandins, leukotrienes, acetylcholine, serotonin and
substance P all affect the nociceptors directly by lowering
their threshold for activation. After tissue damage, a noci-
ceptor responds to the same stimulus given before the injury
occurred with a greater number of action potentials. In addi-
tion, some of the substances just listed can activate the noci-
ceptors directly, resulting in a further increase in nocicep-
tive input into the CNS. Potassium, serotonin, bradykinin
and histamine all have been identified as activators of the
peripheral nociceptors. Activated nociceptors also can
release chemical agents (e.g., substance P and CGRP) at the
peripheral terminal that can either sensitize or activate other
nearby nociceptors. These chemical agents are synthesized
in the cell body (in the dorsal root ganglion) and are trans-
ported down to the peripheral terminal. 
Secondary hyperalgesia
Secondary hyperalgesia occurs during severe or persistent
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increase the firing of neurons in the dorsal horn. This phe-
nomenon is called “wind-up” , and is dependent on the
release of excitatory neurotransmitters (glutamate) from the
C fibers, resulting in long-term changes in the sensitivity of
the dorsal horn neurons, known as “central sensitization”. 
6. Hypoalgesia 
Hypoalgesia is defined as “Diminished pain in response to
a normally painful stimulus”. Hypoalgesia can be achieved
by several mechanisms, all of which involve changes in the
central synapses. These alterations in central synapses also
help determine the overall level of tolerance for pain, or
more specifically, the threshold for the perception of pain. 
7. Neuralgia 
Neuralgia is referred to as “Pain in the distribution of a
nerve or nerves.” Pain associated with neuralgia is often
described as either lancinating or paroxysmal in quality.
The pain can occur spontaneously or be triggered in
response to minimal stimuli that would not normally elicit
pain (allodynia). The most common example is trigeminal
neuralgia, or tic douloureux, which consists of excruciating,
paroxysmal, electric shock-like facial pain in the distribu-
tion of one branch of the trigeminal nerve (most often the
maxillary division). Pain is often evoked by a tactile stimu-
lus in a particular location, known as the trigger zone. 
8. Neurogenic pain 
Neurogenic pain is defined as “Pain initiated or caused by
a primary lesion, dysfunction, or transitory perturbation in
the peripheral or central nervous system.” Neurogenic pain
normally involves the sensitization of nociceptors, dorsal
root ganglia and dorsal horn neurons. This includes both
central sensitization and the wind-up phenomenon. Normal-
ly, polymodal nociceptors have little or no spontaneous
activity. However, after an injury they become sensitized,
resulting in increased spontaneous activity, decreased
threshold, increased sensitivity to heat or cold, sensitivity to
sympathetic stimulation, and an antidromic release of neu-
ropeptides. The clinical characteristics of neurogenic pain
are spontaneous pain (burning, aching, or shocklike), hyper-
algesia and allodynia. Neurogenic pain includes deaf-
ferentation pain, sympathetically maintained pain and neu-
ropathic pain (Fig. 3). 
Deafferentation pain
This type of pain may be a complication of an injury any-
where along the course of the somatosensory pathway. For
example, phantom limb pain is associated with the peripher-
al nerves and spinal cord dysfunction after amputation,
whereas multiple sclerosis can cause dysesthesia and pain
resulting from demyelination in the spinal cord or brain
stem. In addition, thalamic syndromes can lead to a severe
burning sensation (dysesthesia) after a localized lesion
within the thalamus.
Sympathetically maintained pain
This condition is most often characterized by the simulta-
neous occurrence of pain, local autonomic dysregulation
(e.g., edema, vasomotor disturbances, abnormal sweating)
and trophic changes in the skin, soft tissues and bone. These
changes are most often associated with lesions of the
peripheral nerves or nerve roots. Normally most nociceptive
afferents show considerable divergence as they enter the
dorsal horn, and many nociceptive afferents activate direct-
ly or indirectly multiple interneurons, reflex pathways, sec-
ond-order neurons and sympathetic neurons. The activation
of these sympathetic neurons in the intermediolateral cell
column causes changes in blood flow (vasoconstriction or
vasodilation, as well as swelling, edema and possibly troph-
ic changes) that assist in healing. However, this also con-
60 / ASJ: Vol. 4, No. 1, 2010
Fig. 3. Definition of pain.tributes to sensitization and direct activation of the nocicep-
tors at and near the site of the injury (primary hyperalgesia),
resulting in increased sensitivity to pain. When these nor-
mal physiological responses continue past the time of heal-
ing, they can become pathological in nature and contribute
to sympathetically maintained pain. Two types have been
recognized: reflex sympathetic dystrophy or complex
regional pain syndrome (CRPS) I, and causalgia or CRPS
II. CRPS I develops after an initiating noxious event,
whereas CRPS II develops after a nerve injury. 
Neuropathic pain
Neuropathic pain is defined as  “Pain initiated or caused by
a primary lesion or dysfunction in the nervous system.” It is
a type of neurogenic pain that is normally associated with
painful nerve compression (e.g., Intervertebral disc compres-
sion of a dorsal root or dorsal root ganglion) or after the for-
mation of posttraumatic neuromas subsequent to a nerve
lesion. This results in abnormal firing of the nerves in the
areas of demyelination, selective loss of large fiber-mediated
segmental inhibition, and an increased activity of the small
nociceptive fibers. The increased activity of the nociceptive
fibers is believed to be mediated by local changes in extra-
cellular ionic concentrations (increased Na+ and decreased
K+ ions), which result in depolarization of the unmyelinated
and demyelinated fibers [5]. 
9. Nociceptive pain 
Nociceptive pain is defined as “Pain induced by direct
stimulation of nociceptive afferents.” Portenoy and Kanner
[6] defined nociceptive pain as “pain that is believed to be
commensurate with the presumed degree of ongoing activa-
tion of peripheral nociceptors.” Nociceptive pain is related
directly to the activation of normal pain mechanisms in
response to tissue injury. Therefore, any injury or condition
that causes an increase in the normal activity of the nocicep-
tive afferents may cause nociceptive pain if that increase in
activity is recognized by the cortex. Indeed, most nocicep-
tive pain is often more severe than the perceived intensity of
the stimulus due to the extensive network of inhibitory con-
nections that exist to alter the threshold for the perception of
pain. The severity of an injury is not always related directly
to the amount of pain perceived by the subject. Some overt
injuries can produce an obvious painful condition. Howev-
er, there are many stimuli (e.g., changes in the local extra-
cellular ion concentrations) that can activate the nociceptors
without obvious trauma or injury to the site of the painful
condition. Acute pain is most often attributable to some
trauma or altered condition that activates the nociceptors
directly [7]. However, chronic pain is more difficult to
define and treat because the initial cause of the pain (activa-
tion of nociceptors) can be altered dramatically by central
mechanisms. Stimulation of the nociceptors resulting from
an initial injury may be dissociated from the ongoing per-
ception of pain long after the injury has healed due to
changes in the second-order fibers, interneurons and
descending pathways. Therefore, chronic pain may no
longer be attributable to nociceptive pain. 
Many of the structures in and around the lower back are
potential pain generators that can initiate nociceptive pain.
These structures include the muscle, tendons, joint capsules,
periosteum, perivenous tissues (nervi vasorum), visceral tis-
sues, transverse and spinous processes, spinal ligaments, Z
joints, as well as the intervertebral discs and nerves them-
selves (nervi nervorum). 
10. Pain threshold 
The pain threshold is defined as “The least experience of
pain which a subject can recognize.” The threshold was
described traditionally as the lowest stimulus intensity at
which a subject would perceive pain. This term (stimulus
intensity) was excluded from the current definition because
the stimulus intensity is an external measure used to elicit a
response from the subject and cannot be a measure of pain.
However, pain is an experience defined by the subject, and
consequently, highly subjective. Therefore, the threshold is
also highly subjective and related directly to the subject’ s
current disposition. A subject who is energetic, feeling
good, and in good health will most likely have a higher tol-
erance (higher threshold) to pain than a subject who is tired,
injured, or suffering the effects of a cold, flu, or other seem-
ingly unrelated illnesses. 
Treatment 
1. Gate control theory 
Pain transmission cells (T-cells) are located in the dorsal
horn of the spinal cord. The T-cells receive a nociceptive
stimulus from both peripheral pain sensory fibers (small-
diameter fiber, S-fiber) and non-nociceptive sensory nerve
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trol theory states that the L-fibers decrease the afferent sen-
sory input to the T-cell by stimulating the inhibitory
interneuron at the substantia gelatinosa (SG), whereas the
S-fibers increase the afferent sensory input by inhibiting the
inhibitory interneuron at the SG [6]. 
This concept has led to effective treatments for the relief
of pain, such as transcutaneous electrical nerve stimulation
(TENS) and dorsal column stimulation. TENS increases the
activity of the L-fibers, and competitively inhibits pain-con-
ducting fibers (S-fibers) by stimulating the peripheral sen-
sory nerve at low intensity and high frequency. Dorsal col-
umn stimulation activates the inhibitory interneurons at the
SG, which then decrease the activity of the T-cells [8]. 
2. Analgesics 
Analgesics are defined as substances that “cause and
absence or deadening of pain without a loss of conscious-
ness.” Figures 4 and 5 describe the action mechanisms of
each drug [9,10].
Morphinergic drugs 
These drugs participate in the pathway between the inter-
nal analgesic system, and macula nucleito spinal cord. The
internal analgesic system exists paraaxially at the gray
mater around central canal, upper medulla (raphe nuclei)
and spinal cord [11]. 
Tricyclic antidepressants
These drugs activate the descending inhibitory pathway
that normally works during acute pain. Therefore, they are
effective in neuropathic pain but are contraindicated in nar-
row angle glaucoma, benign prostatic hypertrophy, and an
acute myocardial infarction [12]. 
Anticonvulsants 
Drugs, such as phenytoin, carbamazepine, block the neu-
rotransmitter and ion channels. 
Gabapentin 
Gabapentin is an example of an anticonvulsant that acts
on the spinal cord inhibitory interneurons. Caution is need-
ed when administering Gabapentin to patients diagnosed
with nephrotic syndrome.
Local anesthetics
Sensory impulses from the peripheral nociceptors are
converted into pain fiber action potentials. These action
potentials are governed by voltage-gated Na+ channels,
which are blocked by local anesthetics. Caution should be
taken when administering these to patients with cardiac
conduction abnormalities, as well as left ventricle and renal
insufficiency.
NMDA receptor inhibitors
Drugs, such as ketamine, dextromethorphan, reduce pain
by blocking the NMDA receptor at the dorsal horn of the
spinal cord. 
Steroids 
After a tissue injury, activated phospholipase A catalyzes
the conversion of prostaglandins from arachidonic acid via
the cyclooxygenase pathway. Prostaglandins are known to
induce pain. A steroid blocks the conversion of arachidonic
acid to prostaglandins. Recently, it was discovered that the
62 / ASJ: Vol. 4, No. 1, 2010
Fig. 4. The level of action in analgesics. NE: Norepinephrine,
SHT: Serotonin.
Fig. 5. The pharmacological action of analgesics. NSAIDs:
Non-steroidal anti-inflammatory drugs, NMDA: N-methyl-D-
aspartate, GABA: Gamma-aminobutyric acid, Sub-P: Sub-
stance P, CGRP: Calcitonin gene related peptide, NK-A: Neu-
rokinin A.lipooxygenase pathway may also contribute to the produc-
tion of pain.
NSAIDs (non-steroidal anti-inflammatory drug)
These drugs decrease the PGs by inhibiting cyclooxyge-
nase.  
Conclusions  
Pain is an early signal and a red alert to protect an indi-
vidual from tissue injury. The causative factors initially
activate the pain mechanisms but pain itself is caused by a
variety of mechanisms. Therefore, same diseases produce
various types of pain via a range of pain mechanisms, and
some of the characteristics of pain are produced by a variety
of causative diseases. The treatment strategy of pain should
be directed to eradicating both the causative diseases and
the symptoms of pain itself.  
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